DibbsBarker appoints life science and healthcare expert
26 August, 2015Law firm DibbsBarker has announced the appointment of Andrew Rankine as a new special counsel in the company's Sydney office.
Linkage grant to improve diagnostic imaging
21 August, 2015Clarity Pharmaceuticals and the University of Melbourne have been awarded an ARC Linkage grant to fund the development of new agents for diagnostic imaging using PET. The ultimate aim of the project is to try to improve molecular imaging of the brain for various disorders.
Advancing Australia's cell therapy
21 August, 2015A strategic cooperation agreement between CTM CRC, GE Healthcare Australia and HealthInSA outlines a long-term partnership focused on advancing Australia's cell therapy industry.
Paradigm Biopharmaceuticals lists on ASX, announces clinical trial
20 August, 2015Drug developer Paradigm Biopharmaceuticals has listed on the Australian Securities Exchange for the first time.
ROI slipping in biomedical research
18 August, 2015The increasing amount of money spent on biomedical research in the US over the past 50 years has resulted in diminished return on investment in terms of life-expectancy gains and new drug approvals, according to researchers from the Johns Hopkins Bloomberg School of Public Health.
IDT generic drug products to be commercialised in the US
12 August, 2015US-based company ANI Pharmaceuticals has agreed to market and distribute up to 18 generic pharmaceutical products which have recently been acquired by IDT Australia.
Stem cell trial for knee osteoarthritis underway
10 August, 2015 by Lauren DavisRegeneus shares jumped over 20% as the regenerative medicine company announced the first patient to be treated by Progenza, its mesenchymal stem cell therapy treatment for knee osteoarthritis.
Research collaboration to treat pulmonary fibrosis
07 August, 2015Pharmaxis and Synairgen will develop a selective inhibitor to the LOXL2 enzyme to treat the lung disease idiopathic pulmonary fibrosis — a fatal condition that causes persistent and progressive scarring of the alveoli in the lungs.
3D-printed drug approved for epilepsy treatment
06 August, 2015A 3D-printed drug product has been approved by the US FDA for the treatment of partial onset seizures, myoclonic seizures and primary generalised tonic-clonic seizures in adults and children with epilepsy.
Adherium launches IPO prior to ASX listing
05 August, 2015Digital health technology manufacturer Adherium is seeking to raise a maximum of $35 million in the lead-up to its listing on the ASX.
Bionomics appoints chief business officer
03 August, 2015Bionomics Chief Business Officer Tony Colasin will lead corporate development for the company, including business development and strategic opportunities.
ResMed to acquire Curative Medical
31 July, 2015Sleep disorder device supplier ResMed has signed a definitive agreement to acquire its Chinese counterpart Curative Medical.
Manufacturing MSCs to treat heart disease
30 July, 2015Cynata Therapeutics is collaborating with the University of Sydney to test the potential therapeutic efficacy of its Cymerus mesenchymal stem cells (MSCs) in animal models of heart attack and associated heart rhythm abnormalities.
Call for a strategic effort towards advanced manufacturing
30 July, 2015Australia is in the position to secure a globally competitive, locally based advanced manufacturing sector, according to CSL CFO Gordon Naylor.
Ethnic diversity and global drug development
29 July, 2015 by GlaxoSmithKlineOngoing research by GSK’s Ethnopharmacology Group led by Dr Annette Gross is investigating the potential for inter-ethnic differences in response to new medicines being developed by GSK R&D.
